Su et al. on the other hand reported overexpression of BCYRN1 in gliomas and found that it targets the BC200/miR218-5p signaling axis to overcome T mozolamide resistance and inhibit tumor growth [37]. This evidence concerns the gene BCYRN1 and central nervous system cancer.